Skip to main content
Menu
Revvity logo
Contact us

Loading...

US
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Login/Register here
Revvity web shop online account

Get exclusive pricing on all online purchases.

Login to your Revvity.com account for your account's pricing, easy re-ordering from favorites & order history, priority order processing, and dynamic order tracking.

Login Register
Revvity Omics portal accounts

Initiate a new order or access test status and results for clinical genomics or newborn screening services.

View login options
Breadcrumb
...
  • Home
  • Inhibiting interleukin 11 signaling reduces and reverses many dangerous effects of NAFLD/NASH in mouse models
Literature - Publication Review

Inhibiting interleukin 11 signaling reduces and reverses many dangerous effects of NAFLD/NASH in mouse models

inhibiting-interleukin512

Accumulation of fat in liver cells, a process called steatosis, is a common health problem that has many possible causes. Nonalcoholic fatty liver disease (NAFLD) is a group of conditions caused by the buildup of fat in the liver, with some sources estimating that one in four people develop it in their lifetime. NAFLD, if left untreated, may progress to nonalcoholic steatohepatitis (NASH). Dr. Anissa A. Widjaja and colleagues recently examined the connection between interleukin 11 (IL-11) signaling and the development of liver disease. Read more about her study.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Inhibiting interleukin 11 signaling reduces and reverses many dangerous effects of NAFLD/NASH in mouse models

Download Literature - Publication Review
Revvity Logo

Loading...

    ©2025 Revvity - All rights reserved

    Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.